Tags

Type your tag names separated by a space and hit enter

The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
Allergy 2014; 69(6):810-3A

Abstract

KIT D816V is present in a majority of patients with systemic mastocytosis (SM). We determined the KIT D816V allele burden by quantitative real-time PCR in bone marrow and peripheral blood of 105 patients with mastocytosis. KIT D816V was detected in 92/105 patients (88%). Significant differences in the median allele burden were observed between disease subgroups: cutaneous mastocytosis (0.042%), indolent SM (0.285%), smoldering SM (5.991%), aggressive SM (9.346%), and SM with associated hematologic non-mast cell lineage disease (3.761%) (P < 0.001). The KIT D816V burden also correlated with serum tryptase (R = 0.5, P < 0.005) but not with mast cell infiltration in bone marrow or mediator symptoms. Moreover, the allele burden was of prognostic significance regarding survival (P < 0.01). Patients responding to cytoreductive therapy showed a significant decrease in KIT D816V (P < 0.05). To conclude, the KIT D816V burden correlates with the variant of mastocytosis, predicts survival, and is a valuable follow-up parameter in SM.

Authors+Show Affiliations

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24750133

Citation

Hoermann, G, et al. "The KIT D816V Allele Burden Predicts Survival in Patients With Mastocytosis and Correlates With the WHO Type of the Disease." Allergy, vol. 69, no. 6, 2014, pp. 810-3.
Hoermann G, Gleixner KV, Dinu GE, et al. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy. 2014;69(6):810-3.
Hoermann, G., Gleixner, K. V., Dinu, G. E., Kundi, M., Greiner, G., Wimazal, F., ... Sperr, W. R. (2014). The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy, 69(6), pp. 810-3. doi:10.1111/all.12409.
Hoermann G, et al. The KIT D816V Allele Burden Predicts Survival in Patients With Mastocytosis and Correlates With the WHO Type of the Disease. Allergy. 2014;69(6):810-3. PubMed PMID: 24750133.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. AU - Hoermann,G, AU - Gleixner,K V, AU - Dinu,G E, AU - Kundi,M, AU - Greiner,G, AU - Wimazal,F, AU - Hadzijusufovic,E, AU - Mitterbauer,G, AU - Mannhalter,C, AU - Valent,P, AU - Sperr,W R, Y1 - 2014/04/17/ PY - 2014/03/05/accepted PY - 2014/4/23/entrez PY - 2014/4/23/pubmed PY - 2014/12/30/medline KW - KIT D816V KW - allele burden KW - mastocytosis KW - survival KW - treatment response SP - 810 EP - 3 JF - Allergy JO - Allergy VL - 69 IS - 6 N2 - KIT D816V is present in a majority of patients with systemic mastocytosis (SM). We determined the KIT D816V allele burden by quantitative real-time PCR in bone marrow and peripheral blood of 105 patients with mastocytosis. KIT D816V was detected in 92/105 patients (88%). Significant differences in the median allele burden were observed between disease subgroups: cutaneous mastocytosis (0.042%), indolent SM (0.285%), smoldering SM (5.991%), aggressive SM (9.346%), and SM with associated hematologic non-mast cell lineage disease (3.761%) (P < 0.001). The KIT D816V burden also correlated with serum tryptase (R = 0.5, P < 0.005) but not with mast cell infiltration in bone marrow or mediator symptoms. Moreover, the allele burden was of prognostic significance regarding survival (P < 0.01). Patients responding to cytoreductive therapy showed a significant decrease in KIT D816V (P < 0.05). To conclude, the KIT D816V burden correlates with the variant of mastocytosis, predicts survival, and is a valuable follow-up parameter in SM. SN - 1398-9995 UR - https://www.unboundmedicine.com/medline/citation/24750133/The_KIT_D816V_allele_burden_predicts_survival_in_patients_with_mastocytosis_and_correlates_with_the_WHO_type_of_the_disease_ L2 - https://doi.org/10.1111/all.12409 DB - PRIME DP - Unbound Medicine ER -